Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Janssen-Cilag Pty Ltd
Scientific Title
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.